Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis.

Mairéad Geraldine McNamaraMelissa FrizzieroTimothy JacobsAngela LamarcaRichard A HubnerJuan W ValleEitan Amir

Published in: Therapeutic advances in medical oncology (2020)

Second-line therapy for patients with advanced EP-PD-NEC has limited efficacy and the variety of regimens used is diverse. Ki-67>55% is associated with worse outcomes. Prospective randomised studies are warranted to enable exploration of new treatment strategies.

Keyphrases

clinical trial
pulmonary hypertension
open label
study protocol
double blind
type diabetes
squamous cell carcinoma
radiation therapy
placebo controlled
combination therapy
insulin resistance